Abstract：
OBJECTIVE: To report the long term visual outcomes and complications with use of the novel CM-T Flex scleral fixated intraocular lens (CMT-SFIOL).
METHODS: 116 eyes that underwent CMT-SFIOL were reviewed and 57 eyes with CMT-SFIOL that completed a 2-year follow-up were included. Main outcome measures noted were best-corrected visual acuity (BCVA) and complications. Postoperatively, follow-ups were done at 1 week (1w), 1 month (1 m), 1 year (1y) and 2-year (2y) intervals.
RESULTS: 40 (70.17%) of 57 eyes received CMT-SFIOL for surgical aphakia. Mean follow up was 39.77 ± 8.44 months. BCVA for distance & near improved from 1.26 ± 0.84 to 0.76 ± 0.77, 0.50 ± 0.72 and 0.51 ± 0.73 & 1.28 ± 0.58 to 0.98 ± 0.49, 0.92 ± 0.44 and 0.89 ± 0.40 at 1 m, 1y and 2y respectively (p < 0.001 for all). At 1w, 10 eyes (17.54%) had corneal edema (CE) and 8 eyes (14.03%) had anterior chamber (AC) reaction. Two eyes (3.50%) had IOP > 30 mm Hg and 1 eye (1.75%) had vitreous hemorrhage (VH). At 1 m, 3 eyes (5.26%) had CE and 5 eyes (8.77%) had AC reaction. Two eyes (3.50%) had IOP > 30 mm Hg and 1 eye (1.75%) had VH. Cystoid macular edema was noted in 3 eyes (5.26%). At 1y and 2y, 2 eyes (3.5%) and 1 eye (1.75%), had CE. No decentration, dislocation, haptic exposure or retinal detachment was noted. No eyes required resurgery.
CONCLUSIONS: CM-T Flex SFIOL is an effective method to correct aphakia, with reliable and safe long-term results.
METHODS: 116 eyes that underwent CMT-SFIOL were reviewed and 57 eyes with CMT-SFIOL that completed a 2-year follow-up were included. Main outcome measures noted were best-corrected visual acuity (BCVA) and complications. Postoperatively, follow-ups were done at 1 week (1w), 1 month (1 m), 1 year (1y) and 2-year (2y) intervals.
RESULTS: 40 (70.17%) of 57 eyes received CMT-SFIOL for surgical aphakia. Mean follow up was 39.77 ± 8.44 months. BCVA for distance & near improved from 1.26 ± 0.84 to 0.76 ± 0.77, 0.50 ± 0.72 and 0.51 ± 0.73 & 1.28 ± 0.58 to 0.98 ± 0.49, 0.92 ± 0.44 and 0.89 ± 0.40 at 1 m, 1y and 2y respectively (p < 0.001 for all). At 1w, 10 eyes (17.54%) had corneal edema (CE) and 8 eyes (14.03%) had anterior chamber (AC) reaction. Two eyes (3.50%) had IOP > 30 mm Hg and 1 eye (1.75%) had vitreous hemorrhage (VH). At 1 m, 3 eyes (5.26%) had CE and 5 eyes (8.77%) had AC reaction. Two eyes (3.50%) had IOP > 30 mm Hg and 1 eye (1.75%) had VH. Cystoid macular edema was noted in 3 eyes (5.26%). At 1y and 2y, 2 eyes (3.5%) and 1 eye (1.75%), had CE. No decentration, dislocation, haptic exposure or retinal detachment was noted. No eyes required resurgery.
CONCLUSIONS: CM-T Flex SFIOL is an effective method to correct aphakia, with reliable and safe long-term results.
摘要：
目的：报告使用新型CM-TFlex巩膜固定人工晶状体（CMT-SFIOL）的长期视力结果和并发症。
方法：分析了116只行CMT-SFIOL的眼睛，纳入57只行CMT-SFIOL的眼睛，完成了2年的随访。主要结果指标为最佳矫正视力（BCVA）和并发症。术后,随访1周（1w），1个月（1米），1年（1y）和2年（2y）间隔。
结果：57只眼睛中有40只（70.17％）接受了CMT-SFIOL治疗手术无晶状体眼。平均随访39.77±8.44个月。距离和近处的BCVA在1米时从1.26±0.84提高到0.76±0.77、0.50±0.72和0.51±0.73以及1.28±0.58提高到0.98±0.49、0.92±0.44和0.89±0.40，分别为1y和2y(全部p<0.001)。在1w，10只眼(17.54%)出现角膜水肿(CE),8只眼(14.03%)出现前房(AC)反应。2眼(3.50%)眼压>30mmHg,1眼(1.75%)玻璃体出血(VH)。在1米,3只(5.26%)眼出现CE反应,5只(8.77%)眼出现AC反应。两只眼睛（3.50％）的IOP>30mmHg，一只眼睛（1.75％）的VH。黄斑囊样水肿3眼(5.26%)。在1y和2y，2只眼（3.5%）和1只眼（1.75%），有CE。没有分权,位错,注意到触觉暴露或视网膜脱离。没有眼睛需要复活。
结论：CM-TFlexSFIOL是纠正无晶状体眼的有效方法，具有可靠和安全的长期结果。
方法：分析了116只行CMT-SFIOL的眼睛，纳入57只行CMT-SFIOL的眼睛，完成了2年的随访。主要结果指标为最佳矫正视力（BCVA）和并发症。术后,随访1周（1w），1个月（1米），1年（1y）和2年（2y）间隔。
结果：57只眼睛中有40只（70.17％）接受了CMT-SFIOL治疗手术无晶状体眼。平均随访39.77±8.44个月。距离和近处的BCVA在1米时从1.26±0.84提高到0.76±0.77、0.50±0.72和0.51±0.73以及1.28±0.58提高到0.98±0.49、0.92±0.44和0.89±0.40，分别为1y和2y(全部p<0.001)。在1w，10只眼(17.54%)出现角膜水肿(CE),8只眼(14.03%)出现前房(AC)反应。2眼(3.50%)眼压>30mmHg,1眼(1.75%)玻璃体出血(VH)。在1米,3只(5.26%)眼出现CE反应,5只(8.77%)眼出现AC反应。两只眼睛（3.50％）的IOP>30mmHg，一只眼睛（1.75％）的VH。黄斑囊样水肿3眼(5.26%)。在1y和2y，2只眼（3.5%）和1只眼（1.75%），有CE。没有分权,位错,注意到触觉暴露或视网膜脱离。没有眼睛需要复活。
结论：CM-TFlexSFIOL是纠正无晶状体眼的有效方法，具有可靠和安全的长期结果。
